Axillary Hyperhidrosis Pipeline Market Research Report 2022 featuring Brickell Biotech, Dermata Therapeutics, Eirion Therapeutics, Theravida, GlaxoSmithKline, & Medytox

DUBLIN, April 21, 2022–(BUSINESS WIRE)–The “Axillary Hyperhidrosis – Pipeline Insight, 2022” clinical trials have been added to ResearchAndMarkets.com’s offering.

The “Axillary Hyperhidrosis – Pipeline Insight, 2022” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Axillary Hyperhidrosis pipeline landscape.

It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

The assessment part of the report embraces in depth Axillary Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axillary Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

Companies and academics are working to assess challenges and seek opportunities that could influence Axillary Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Axillary Hyperhidrosis.

Axillary Hyperhidrosis Emerging Drugs Chapters

This segment of the Axillary Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axillary Hyperhidrosis Emerging Drugs

Sofpironium bromide: Brickell Biotech Inc.

Sofpironium bromide is a new chemical entity that we are currently developing in the US as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The drug is a retro metabolically designed anticholinergic agent which selectively binds to M3 AC receptor potentially inhibiting sweat production.

ET-01: Eirion Therapeutics

ET-01 is a topical botulinum product being developed with the goal of avoiding the pain, bleeding and bruising that can be associated with the injection of commercially available botulinum products. ET-01 employs a nanoemulsion transdermal delivery technology essential for a large molecule such as botulinum to penetrate into the skin. The drug is currently being developed in Phase 2 stage of development for the treatment of Axillary Hyperhidrosis.

DMT410: Dermata Therapeutics LLC pipeline

DMT410 is the second development program using DMT400 combination regimen in combination with botulinum toxin. Dermata Therapeutics has completed a proof of concept, Phase 1 clinical trial using DMT410 in combination with BOTOX for the treatment of primary axillary hyperhidrosis. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using injections of BOTOX.

Axillary Hyperhidrosis: Therapeutic Assessment

This segment of the report provides insights about the different Axillary Hyperhidrosis drugs segregated based on the following parameters that define the scope of the report, such as:

Major Players in Axillary Hyperhidrosis

There are approx. 3+ key companies which are developing the therapies for Axillary Hyperhidrosis. The companies which have their Axillary Hyperhidrosis drug candidates in the most advanced stage, ie phase III include, Brickell Biotech Inc.

Key Players

  • Brickell Biotech Inc.

  • Dermata Therapeutics LLC

  • Eirion Therapeutics

  • Theravida

  • GlaxoSmithKline

  • Meditox

Key Products

  • Sofpironium bromide

  • ET-01

  • DMT410

  • Umeclidinium

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/pfx0xo

View source version on businesswire.com: https://www.businesswire.com/news/home/20220421005722/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For EST Office Hours Call 1-917-300-0470
For US/CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Leave a Comment

Your email address will not be published. Required fields are marked *